CML Publications January 2025

The face of Professor Tim Hughes
Professor Timothy Hughes

As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications from low- and middle-income countries.

Clinical publications

Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial
Jabbour E et al. JAMA Oncol, January 2025

Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life
Cho HJ et al. Acta Haematol, January 2025 (epub ahead of print)

Bosutinib for the treatment of CML – using it safely: a Podcast
Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print)
open access publication

The evolution of treatment-free remission
Hughes TP et al. Blood, January 2025 (epub ahead of print)

The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
Qian Z et al. Bioorg Chem, January 2025 (epub ahead of print)

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different?
Maduado C et al. ESC Heart Fail, January 2025 (epub ahead of print)
open access publication

Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review
Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025

Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
Li Z et al. Cancer, January 2025
open access publication

Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib
Yu L et al. Cancer, January 2025
open access publication

Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid)
Sasaki K. Cancer, January 2025

Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
Kondo T et al. Cancer, January 2025
open access publication

Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group
Giordano U et al. Biomedicines, January 2025
open access publication

Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia
Mayer J et al. Am J Hematol, January 2025 (epub ahead of print)
open access publication

Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases
Yousefi A et al. Ann Hematol, January 2025 (epub ahead of print)
open access publication

Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study
Szuber N et al. Future Oncol, January 2025 (epub ahead of print)
open access publication

Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice
Aleem A et al. Clin Lymphoma Myeloma Leuk, January 2025

Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy
Shen Q et al. Leuk Lymphoma, January 2025 (epub ahead of print)

Scientific publications

Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line
Jaafari N et al. PLoS, January 2025
open access publication

Exploring the significance of MDM2 gene promotes variants in chronic myeloid leukemia
Fontecha MB et al. Leuk Res, January 2025 (epub ahead of print)

N-Degron PROTACs as a potential therapeutic approach for chronic myeloid leukemia
Hohmann G & Eldeeb MA. Anticancer Agents Med Chem, January 2025 (epub ahead of print)

Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL positive leukemia
Luo Z et al. Cancer Res, January 2025
open access publication

Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells
Sun X et al. Biochem Pharmacol, January 2025 (epub ahead of print)

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
Minhajuddin M et al. Haematologica, January 2025
open access publication

LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting
Quijada-Alamo M et al. Haematologica, January 2025 
open access publication

Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
Komic H et al. Haematologica, January 2025
open access publication

High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia
Nygren PJ et al. Blood, January 2025 (epub ahead of print)

Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells
Rocco S et al. J Clin Med, January 2025
open access publication

EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia
Brunmeier R et al. Leukemia, January 2025 (epub ahead of print)
open access publication

Pediatric CML publications

Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric low middle-income country (LMIC) patients
Bukhari SI et al. Cancer Invest, January 2025 (epub ahead of print)

Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
Seiser E et al. J Mol Diagn, January 2025 (epub ahead of print)

LMIC publications

Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric low middle-income country (LMIC) patients
Bukhari SI et al. Cancer Invest, January 2025 (epub ahead of print)

Haemolytic anemia in a patient of chronic myeloid leukemia: an unrecognised side-effect
Jamal I et al. Niger Med J, January 2025
open access publication

Management of CML and pregnancy in low- and middle-income countries
Malhotra N et al. Indian J Hematol Blood Transf, January 2025